Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Jan 05, 2017, 08:00 ET PaxVax Partners with National Institutes of Health and Department of Defense to Develop a New Virus-Like Particle Vaccine to Fight the Spread of Chikungunya

PaxVax announced today its partnership with the National Institutes of Health (NIH) and United States Department of Defense (DoD) on its...


Jan 05, 2017, 08:00 ET PTC Therapeutics Announces Initiation of FIREFISH Study in Infant (Type I) SMA Patients

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its joint development program in Spinal Muscular Atrophy (SMA) with Roche and the SMA...


Jan 05, 2017, 08:00 ET Amorsa Therapeutics Announces Strategic Collaboration Facilitated by Johnson & Johnson Innovation to Develop New Therapy for Treatment-Resistant Depression

Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for nervous system disorders has...


Jan 05, 2017, 07:00 ET Halozyme Announces Phase 2 Study In Advanced Pancreas Cancer Meets Key Endpoints

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported topline results from the combined analysis of Stages 1 and 2 and Stage 2 alone of its...


Jan 05, 2017, 06:59 ET Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)

Janssen Biotech, Inc. today announced that the company has entered a clinical trial collaboration with Bristol-Myers Squibb Company (BMS) to...


Jan 05, 2017, 06:58 ET Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI)

Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and...


Jan 05, 2017, 06:00 ET Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases...


Jan 05, 2017, 03:00 ET Enterome Starts Phase I Clinical Trial With its Lead Candidate EB8018 to Treat Crohn's Disease

EB8018 is a first-in-class oral small molecule targeting the host-microbiome interaction by blocking FimH ENTEROME SA, a pioneer in the...


Jan 05, 2017, 01:30 ET CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib

CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the full clinical hold (February 2016) implemented by the U.S. Food...


Jan 05, 2017, 00:37 ET Sun Pharma annonce des résultats initiaux positifs pour l'essai clinique de confirmation de phase 3 de Seciera™ pour le traitement de la sécheresse oculaire

- Seciera™ satisfait les critères d'évaluation primaires et les principaux critères d'évaluation secondaires lors de l'essai pivot - Se révèle...


Jan 04, 2017, 22:44 ET Sun Pharma anuncia resultados positivos de línea superior del ensayo clínico de fase 3 confirmatorio para Seciera™ para tratar el ojo seco

- Seciera™ cumple las conclusiones primarias y secundarias en un ensayo pivotal - Muestra eficacia a las 12 semanas de tratamiento - Sun...


Jan 04, 2017, 18:45 ET Sun Pharma anuncia resultados positivos de primeira linha para o teste clínico fase 3 confirmatório da Seciera™, para tratamento do olho seco

A Sun Pharma anunciou os bem-sucedidos resultados do teste clínico fase 3 confirmatório para Seciera™ (solução oftalmológica de ciclosporina A,...


Jan 04, 2017, 18:01 ET Das Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) bestätigt den Zusatznutzen von Kisplyx® (Lenvatinib) in Kombination mit Everolimus für die Behandlung des fortgeschrittenen Nierenzellkarzinoms

NUR FÜR EU-MEDIEN: NICHT FÜR MEDIEN AUS DER SCHWEIZ UND ÖSTERREICH Jedes Jahr entwickeln rund 15.000 Menschen in Deutschland ein...


Jan 04, 2017, 17:11 ET Sun Pharma anuncia los principales resultados positivos de ensayo clínico confirmatorio de Fase 3 de Seciera™ para el tratamiento de ojo seco

Sun Pharma anunció resultados exitosos de ensayos clínicos confirmatorios de Fase 3 de Seciera™ (ciclosporina A, 0,09% solución oftálmica),...


Jan 04, 2017, 09:30 ET Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Yale University for Treating Tourette's Syndrome Using Cannabinoid-based Drug

Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), the pharma company specializing in the development and commercialization of...


Jan 04, 2017, 09:15 ET BioPharmX Completes Enrollment of BPX-01 Phase 2b OPAL Clinical Trial for Acne Vulgaris

BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the...


Jan 04, 2017, 09:15 ET MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering

MaxCyte®, Inc., a developer and supplier of cell engineering products and technologies to biopharmaceutical firms engaged in cell therapy, drug...


Jan 04, 2017, 09:00 ET CytRx Granted Type B Pre-NDA Meeting with U.S. FDA for Registration Pathway with Aldoxorubicin as a Treatment for Patients with Relapsed Soft Tissue Sarcomas

CytRx Corporation (NASDAQ: CYTR), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new...


Jan 04, 2017, 09:00 ET Neuronix Reports Positive Results From Its Multi-Center Alzheimer's Study At The Clinical Trials In Alzheimer's Disease (CTAD) Conference

Neuronix Ltd. announced positive results from its pivotal double-blind, placebo-controlled, multi-center clinical study for the assessment of the...


Jan 04, 2017, 08:34 ET Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera™ for Treatment of Dry Eye

- Seciera™ Meets Primary and Key Secondary Endpoints in Pivotal Trial - Shows Efficacy at 12 Weeks of Treatment - Sun Pharma is Developing...